Lanean...
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
BACKGROUND: A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma has been identified as a predictor of superior long-term outcome in some, but not all studies. METHODS: To determine if the parameter of M protein reduction was of value in the rela...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4149315/ https://ncbi.nlm.nih.gov/pubmed/21328327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25937 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|